Rixubis Baxalta Innovations GmbH · Authorised · authorised 19 Dec 2014 · ATC B02BD04
Therapeutic indication (EMA)
Treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency).
Active substance
Nonacog gamma
- EMA 1
- Health Canada 3
EMA European Union — centrally authorised medicines
Canada Canada — marketed products (Health Canada)
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.